CYP2A6 and nicotine metabolism: The key enzyme in tobacco addiction.

Amada Mihasan*

Faculty of Biology, Alexandru Ioan Cuza University of Iași, Romania

Introduction

Nicotine addiction remains a major public health concern, with smoking being a leading cause of preventable deaths worldwide. While environmental factors play a role in tobacco dependence, genetic variations significantly influence nicotine metabolism, addiction severity, and smoking cessation outcomes. The enzyme cytochrome P450 2A6 (CYP2A6) is the primary catalyst responsible for nicotine metabolism, converting nicotine into cotinine and other metabolites. Variability in CYP2A6 activity affects smoking behaviors, dependence levels, and treatment responses. This article explores the role of CYP2A6 in nicotine metabolism, its genetic variations, and its implications for tobacco addiction treatment [1].

CYP2A6 is a liver enzyme responsible for oxidizing nicotine into cotinine, the primary nicotine metabolite. The metabolic pathway is as follows: Nicotine enters the bloodstream through smoking, chewing tobacco, or nicotine replacement therapies (NRTs). CYP2A6 oxidizes nicotine into cotinine, which is further broken down into trans-3'-hydroxycotinine (3HC) [2].

Cotinine and 3HC are eventually excreted in urine. The rate at which nicotine is metabolized affects smoking behavior. Fast metabolizers clear nicotine quickly, leading to more frequent smoking to maintain nicotine levels, while slow metabolizers retain nicotine longer, reducing the need for frequent cigarette consumption [3].

Genetic polymorphisms in the CYP2A6 gene result in different nicotine metabolism rates, categorized into: Individuals with fully functional CYP2A6 metabolize nicotine rapidly, often leading to heavier smoking patterns and higher dependence [4].

Those with partially functional CYP2A6 variants break down nicotine at a moderate rate, leading to lower cigarette consumption. Individuals with non-functional CYP2A6 variants metabolize nicotine very slowly, resulting in lower smoking intensity and higher success rates in quitting [5].

Research has shown that people with slow or inactive CYP2A6 variants are less likely to become addicted to nicotine and have an easier time quitting smoking (Bloom et al., 2014). Conversely, fast metabolizers are more likely to smoke more cigarettes per day and have greater difficulty quitting due to faster nicotine clearance [6].

CYP2A6 activity directly influences nicotine dependence. Fast metabolizers experience shorter nicotine half-lives, leading to stronger cravings and increased cigarette consumption. Slow metabolizers maintain nicotine in their system for longer periods, reducing withdrawal symptoms and making them less prone to addiction [7].

The effectiveness of smoking cessation treatments depends on an individual's CYP2A6 metabolism rate: Due to rapid nicotine clearance, they may require higher doses of nicotine replacement therapy (NRT), such as nicotine patches or gum, to maintain adequate nicotine levels. Slow Metabolizers: These individuals respond better to non-nicotine-based treatments like varenicline (Chantix), as they naturally retain nicotine for longer periods, reducing their need for supplementation [8].

Policies can be designed to provide personalized treatment plans for smokers based on their nicotine metabolism rates. Genotyping CYP2A6 can help develop personalized smoking cessation plans. By identifying fast and slow metabolizers, healthcare providers can tailor treatments, optimizing nicotine replacement therapy dosages or recommending alternative medications for improved success rates [9].

Given CYP2A6's role in nicotine metabolism, researchers have explored inhibitors to slow nicotine breakdown, extending nicotine's presence in the body and potentially reducing cigarette consumption. Some promising inhibitors include: A natural compound that inhibits CYP2A6, reducing nicotine metabolism and cravings [10].

Conclusion

CYP2A6 is a key enzyme in nicotine metabolism, playing a crucial role in tobacco addiction and smoking behaviors. Genetic variations in CYP2A6 determine how quickly nicotine is processed, affecting dependence, smoking intensity, and cessation success rates. Recognizing these differences can lead to personalized treatment approaches, improving smoking cessation outcomes. Future research on CYP2A6 inhibitors and genetic screening could revolutionize the way addiction is managed, offering new strategies for reducing smoking rates worldwide.

References

1. Strang J, Volkow ND, Degenhardt L, Hickman M, et al., Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3.
2. Sharma B, Bruner A, Barnett G, Fishman M. Opioid use disorders. Child Adolesc Psychiatr Clin N. 2016;25(3):473-87.

***Correspondence to:** Amada Mihasan, Faculty of Biology, Alexandru Ioan Cuza University of Iași, Romania. E-mail: amada.m@uaic.ro

***Received:** 03-Mar-2025, Manuscript No. AARA-25- 163807; **Editor assigned:** 04-Mar-2025, PreQC No. AARA-25- 163807 (PQ); **Reviewed:** 18-Mar-2025, QC No. AARA-25- 163807; **Revised:** 23-Mar-2025, Manuscript No. AARA-25- 163807 (R); **Published:** 30-Mar-2025, DOI: 10.35841/aara-8.2.258*

***Citation:** Mihasan A. CYP2A6 and nicotine metabolism: The key enzyme in tobacco addiction. Addict Criminol.2025;8(2):258*

3. Kelly JP, Cook SF, Kaufman DW, et al., Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-13.
4. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. The Lancet. 2019;393(10182):1760-72.
5. Schuchat A, Houry D, Guy GP. New data on opioid use and prescribing in the United States. Jama. 2017;318(5):425-6.
6. Pergolizzi Jr JV, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892-903.
7. Degenhardt L, Grebely J, Stone J,et al., Global patterns of opioid use and dependence: harms to populations, interventions, and future action. The Lancet. 2019;394(10208):1560-79.
8. Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-8.
9. Wilder-Smith OH. Opioid use in the elderly. Eur J Pain. 2005;9(2):137-40.
10. Nelson LS, Juurlink DN, Perrone J. Addressing the opioid epidemic. Jama. 2015;314(14):1453-4.

Citation: *Mihasan A. CYP2A6 and nicotine metabolism: The key enzyme in tobacco addiction. Addict Criminol.2025;8(2):258*